Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych et al. show that p53 missense mutants upregulate the proteasome and increase breast cancer cell resistance to proteasome inhibitors. Combined inhibition of p53 mutants and the proteasome leads to increased therapeutic efficacy.